Please assess the completion status of the following clinical trial:

Trial Title: S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed Hodgkin's lymphoma~  * Relapsed or refractory disease~ * Biopsy or radiological evidence of disease at time of recurrence/progression required~* Has received ≥ 1 prior systemic chemotherapy regimen~* No clonal abnormalities in marrow collection~* Must undergo involved-field radiotherapy if bulky disease \> 5 cm~* Must have adequate sections of original diagnostic specimen available for review~  * Needle aspirations or cytologies are not adequate~* No prior lymphoma, myelodysplastic syndromes, or leukemia (even if disease free \> 5 years)~* Patients who relapse after achieving a complete remission must complete a minimum of 2 courses of salvage chemotherapy or radiation therapy to determine if sensitive or resistant recurrent disease is present~* No central nervous system (CNS) involvement~PATIENT CHARACTERISTICS:~Age~* 15 to 70~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~Hepatic~* Bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless due to Hodgkin's disease)~Renal~* Creatinine clearance ≥ 60 mL/min~* Creatinine ≤ 2 times upper limit of normal~Cardiovascular~* None of the following conditions requiring therapy:~  * Coronary artery disease~ * Cardiomyopathy~ * Congestive heart failure~ * Arrhythmias~* Ejection fraction ≥ 45% by Multi Gated Acquisition Scan (MUGA) or 2-D echocardiogram~Pulmonary~* Adequate pulmonary function~* Corrected diffusing capacity of lung for carbon monoxide (DLCO) ≥ 60% OR~* Forced Expiratory Volume in One Side (FEV_1) ≥ 60% of predicted~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer~* No known HIV or AIDS infection~* No active bacterial, fungal, or viral infection~* No medical condition that would preclude study treatment~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- High-dose therapy plus tandem transplant (Type: EXPERIMENTAL): Regimen consists of 2 cycles of high-dose therapy, each followed by stem cell infusion. Cycle 1 consists of high-dose melphalan followed by infusion of approximately 1.5 million cluster of differentiation 34 positive (CD34+) cells. Cycle 2 consists of either TBI-based or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-based high-dose therapy followed by infusion of at least 2 million CD34+ cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).